Form 4: ImageneBio Director Reports Post-Merger Share Holdings

ImageneBio Director Jonathan Wang reported significant direct and indirect share acquisitions following the merger with Inmagene Biopharmaceuticals.

Summary

• Director Jonathan Wang acquired shares in ImageneBio, Inc. (formerly Ikena Oncology, Inc.) on July 25, 2025, following a merger with Inmagene Biopharmaceuticals.
• The merger, based on an agreement dated December 23, 2024, involved two steps: Merger Sub I merging into Legacy Inmagene, followed by Legacy Inmagene merging into Merger Sub II.
• Upon the closing of the merger, each Legacy Inmagene ordinary and preferred share was converted into 0.003051 shares of ImageneBio common stock.
• Wang directly acquired 143,832 shares of common stock in exchange for 47,142,857 Series Seed convertible preferred shares of Legacy Inmagene.
• Wang indirectly acquired 971,173 shares of common stock through Engene Inc., in exchange for 318,313,306 ordinary shares of Legacy Inmagene.
• Engene Inc.'s sole shareholder is YJH Trust, whose beneficiaries are Dr. Wang's spouse and daughter; Dr. Wang disclaims beneficial ownership except for his pecuniary interest.

Sentiment

Score: 6

Explanation: The filing reports a completed merger and subsequent share acquisition, which is a neutral to positive event indicating progress. The minor negative is the late filing, but it is attributed to administrative issues rather than a significant operational problem.

Positives

• The completion of the merger between Ikena Oncology, Inc. and Inmagene Biopharmaceuticals, leading to the formation of ImageneBio, Inc., signifies a strategic consolidation.
• Director Jonathan Wang's significant shareholdings align his interests with the newly formed entity's success.

Negatives

• The Form 4 filing was submitted late due to delays in obtaining the reporting person's EDGAR codes.

Risks

• Administrative delays in obtaining EDGAR codes can lead to late filings, potentially raising minor compliance concerns.

Future Outlook

The filing primarily reports a completed transaction and does not provide explicit forward-looking statements or guidance beyond the details of the merger.

Management Comments

• The Form 4 was filed late due to delays in obtaining the reporting person's EDGAR codes.

Industry Context

The merger of Ikena Oncology, Inc. and Inmagene Biopharmaceuticals to form ImageneBio, Inc. reflects a trend of consolidation within the biotechnology and pharmaceutical sectors, often driven by the desire to combine pipelines, R&D capabilities, and market reach to achieve greater scale and efficiency.

Related Party Transactions

• Jonathan Wang's indirect acquisition of 971,173 shares through Engene Inc., where his spouse and daughter are beneficiaries of the controlling trust, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The merger and subsequent share conversions impact the ownership structure and potentially the future value of shares in the newly formed ImageneBio, Inc.
• Management/Insiders: Director Jonathan Wang's increased stake aligns his interests with the company's performance.

Key Dates

Recommendation

The filing details the completion of a merger and a director's resulting shareholdings, which is a factual report of a corporate event. While the merger itself could be a catalyst, this specific Form 4 does not provide new operational or financial performance data to warrant a strong buy or sell recommendation. The late filing is a minor administrative issue. Investors should 'hold' and await further operational updates from the newly formed entity.

Keywords

ImageneBio, IMA, Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Share Acquisition, Beneficial Ownership, Form 4, Jonathan Wang, Biotechnology, Pharmaceuticals